Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder

被引：12

作者：

Jung, Jeesun ^{[1
]}

Tawa, Elisabeth A. ^{[2
]}

Muench, Christine ^{[2
]}

Rosen, Allison D. ^{[2
]}

Rickels, Karl ^{[3
]}

Lohoff, Falk W. ^{[2
,3
]}

机构：

[1] NIAAA, Div Intramural Clin & Biol Res, Bethesda, MD 20892 USA

[2] NIAAA, Sect Clin Genom & Expt Therapeut, Bethesda, MD USA

[3] Univ Penn, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Philadelphia, PA 19104 USA

来源：

PSYCHIATRY RESEARCH | 2017年 / 254卷

关键词：

Pharmacogenetics; Generalized anxiety disorder; Venlafaxine XR; EXTENDED-RELEASE; EXPRESSION; ANTIDEPRESSANTS; MECHANISMS; IMPUTATION; BEHAVIORS;

D O I：

10.1016/j.psychres.2017.04.025

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p < 0.00001). Several identified genes may indicate markers crossing neuropsychiatric diagnostic categories.

引用

页码：8 / 11

页数：4

共 50 条

[1] Genome-Wide Association Study of Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder
Tawa, Elisabeth A.
Jung, Jeesun
Rosen, Allison
Rickels, Karl
Lohoff, Falk W.
[J]. BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 69S - 69S
[2] Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder
Sheehan, DV
[J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 23 - 28
[3] The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder
Rickels, Karl
Gallop, Robert
Cleary, Sean
[J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (03) : 258 - 260
[4] Long-term treatment of generalized social anxiety disorder with venlafaxine XR
Hackett, D
Stein, MB
Mangano, R
Pollack, M
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S380 - S381
[5] EARLY IMPROVEMENT AND ENDPOINT RESPONSE IN THE ACUTE TREATMENT OF GENERALIZED ANXIETY DISORDER WITH PREGABALIN OR VENLAFAXINE-XR
Baldwin, D. S.
Schweitzer, E.
Lyndon, G.
Donevan, S.
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (08) : A72 - A72
[6] Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder
Kelsey, JE
[J]. DEPRESSION AND ANXIETY, 2000, 12 : 81 - 84
[7] Improvement in functionality with treatment of generalized social anxiety disorder: Venlafaxine XR vs placebo
Mallick, R
Mangano, R
Shrivastava, RK
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S356 - S357
[8] Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder
Meoni, P
Salinas, E
Brault, Y
Hackett, D
[J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (11) : 888 - 893
[9] Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder
Narasimhan, Sneha
Aquino, Tiffany D.
Multani, Pushpinder K.
Rickels, Karl
Lohoff, Falk W.
[J]. PSYCHIATRY RESEARCH, 2012, 198 (01) : 112 - 115
[10] Venlafaxine XR versus fluoxetine in the treatment of major depressive disorder and generalized anxiety disorder dual diagnosis
Vasile, D.
Vasiliu, O.
Ivanov, P.
Ojog, D.
Sarmache, M.
Vasile, M.
[J]. EUROPEAN PSYCHIATRY, 2007, 22 : S247 - S247

← 1 2 3 4 5 →